文献速递心力衰竭与心肌病

沙库巴曲缬沙坦对比依那普利治疗恰加斯病所致射血分数降低心衰:ANSWER-HF随机试验主要结果

Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-11-09

ANSWER-HF是在巴西开展的随机双盲对照试验,纳入190例恰加斯心肌病合并HFrEF患者,随机接受沙库巴曲缬沙坦或依那普利治疗6个月。主要终点LVEF变化组间差异无统计学意义(0.9个百分点,95%CI -0.9至2.6,P=0.36),但沙库巴曲缬沙坦组NT-proBNP显著更低(几何均值比0.68,95%CI 0.57-0.81,P<0.001),安全性相当。

要点

  • 沙库巴曲缬沙坦未显著改善恰加斯心肌病HFrEF患者6个月LVEF
  • 沙库巴曲缬沙坦较依那普利显著降低NT-proBNP
  • 两组安全性结局相当,未发现新的安全信号

核心结论

  • 在恰加斯心肌病合并HFrEF患者中,沙库巴曲缬沙坦治疗6个月未较依那普利显著改善LVEF,但与NT-proBNP更大程度降低相关。
  • 沙库巴曲缬沙坦与依那普利两组安全性结局相当,未发现安全性担忧。

研究设计与样本

  • ANSWER-HF为在巴西开展的随机、双盲、对照试验。
  • 共纳入190例恰加斯心肌病合并HFrEF患者,LVEF<40%、NYHA心功能II-IV级,按1:1随机分配至沙库巴曲缬沙坦或依那普利,随访6个月。
  • 主要终点为基线至6个月LVEF变化;分层次要终点采用win ratio法分析心血管死亡、心衰住院、NT-proBNP变化和LVEF变化。

主要发现

  • 患者平均年龄61岁,女性占40%,黑人或混血种族占69%,基线平均LVEF为30.1%。
  • 6个月时沙库巴曲缬沙坦组平均LVEF增加2.1%,依那普利组增加1.2%,组间差异0.9个百分点(95%CI -0.9至2.6;P=0.36)。
  • 分层分析中沙库巴曲缬沙坦的win数多于依那普利(win ratio 1.80;95%CI 1.27-2.63)。
  • 沙库巴曲缬沙坦组NT-proBNP中位数显著更低(几何均值比0.68;95%CI 0.57-0.81;P<0.001)。
  • 超声心动图重构指标和6分钟步行距离未见显著差异,安全性结局发生情况相当。

临床怎么用

  • 对于恰加斯心肌病合并HFrEF患者,沙库巴曲缬沙坦未显示较依那普利改善LVEF的优势,但可显著降低NT-proBNP,安全性相当。
  • 该试验为该被忽视疾病中开展随机试验的可行性和安全性提供了证据,支持后续开展更大规模以结局为导向的研究。

局限性

  • 样本量190例,随访6个月,可能不足以检测LVEF的组间差异。
  • 主要终点为LVEF变化这一替代终点,而非硬性临床结局。
  • 研究仅在巴西开展,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic Chagas cardiomyopathy (CCC) represents a common cause of nonischemic heart failure with reduced ejection fraction (HFrEF) in Latin America, yet evidence from randomized trials remains scarce. Sacubitril-valsartan has shown benefits in HFrEF of other etiologies, but less is known about its effects on CCC. OBJECTIVES: The authors sought to compare the effects of sacubitril-valsartan vs enalapril on cardiac remodeling, functional outcomes, biomarkers, and safety in patients with CCC and HFrEF. METHODS: ANSWER-HF was a randomized, double-blind, controlled trial in Brazil. A total of 190 patients with CCC and HFrEF (left ventricular ejection fraction [LVEF] <40%, NYHA functional class II-IV) were randomized in a 1:1 ratio to sacubitril-valsartan or enalapril and followed for 6 months. The primary endpoint was change in LVEF from baseline to 6 months. The win ratio method analyzed the hierarchical secondary endpoint of cardiovascular death, heart failure hospitalization, N-terminal pro-B-type natriuretic (NT-proBNP) change, and LVEF change. RESULTS: Mean age was 61 years, 40% women, and 69% Black or mixed race. Baseline mean LVEF was 30.1%. At 6 months, mean LVEF increased by 2.1% with sacubitril-valsartan and 1.2% with enalapril (between-group difference 0.9 percentage points; 95% CI: -0.9 to 2.6; P = 0.36). In hierarchical analysis, sacubitril-valsartan achieved more wins than enalapril (win ratio 1.80; 95% CI: 1.27-2.63). Median NT-proBNP was significantly lower with sacubitril-valsartan (geometric mean ratio 0.68; 95% CI: 0.57-0.81; P < 0.001). No significant differences were observed in echocardiographic remodeling or 6-minute walk distance, and the occurrence of safety outcomes were comparable. CONCLUSIONS: In patients with CCC and HFrEF, sacubitril-valsartan did not result in significant improvements in LVEF compared with enalapril after 6 months, but was associated with a greater reduction in NT-proBNP. No safety concerns were associated with either the sacubitril-valsartan or enalapril group. These findings establish the feasibility and safety of conducting trials in this neglected disease, demonstrate biological activity of sacubitril-valsartan and enalapril in HFrEF due to CCC, and chart the path for larger, outcome-driven studies. The ANSWER-HF represents an important step forward, beginning a new era of evidence generation for Chagas cardiomyopathy. (Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction [ANSWER-HF]; NCT04853758).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Madrini, Souza, Fernandes, et al. Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial. J Am Coll Cardiol. 2025. PMID: 41396086. doi:10.1016/j.jacc.2025.10.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。